Coller Capital Ltd. is an investment firm specializing in direct and fund of funds investments. For direct investments, the firm specializes in late-stage, secondary investments, emerging growth, growth capital, restructuring, spin-off, management buyouts, turnaround, middle market, later stage, mature, mid venture, and management buyin financing. In secondary direct investments, the firm focuses on  early stage, development, successions, buyouts and buy-ins and seeks to take stakes in privately held companies and acquire limited partnership interests in private equity, venture capital, buyouts, mezzanine funds, and secondary fund of fund investments. It seeks to invest across all sectors with a focus on life sciences, telecommunication services, communications equipment, real estate, real assets, infrastructure, credit coming and information and communication technology sectors. The firm invests globally with a focus on Asia, Nordic region, Middle East, Europe (Southern Europe also), Italy, United States, Spain, Portugal, Latin America, and United Kingdom. It also invests in  French speaking, Irish Speaking, and German Speaking markets. It typically invests between $1 million to more than $1 billion in any single transaction. The firm seeks to be the lead investor and prefers to take minority stakes in medium-sized companies. It exits its investments between four years and six years by an initial public offering or a trade sale. Coller Capital Ltd. was founded in 1990 and is based in London, United Kingdom with additional offices in New York, New York and Hong Kong.

Coller Capital

Principal

Partner

Investment Manager

Senior Associate

Partner and Co-Head of Origination

Head and Partner of Markets and Planning

Head and Partner of Talent Management

CIO and Managing Partner

Investment Principal

Partner, Co-Head of Investor Relations and Fundraising

Deputy Managing Partner

Associate

Principal, Investor Relations

BOOK A TIGER raised $21500000 on 2017-02-10 in Series B

BOOK A TIGER is an Integrated Facility Management Platform. It provides customers with access to high quality cleaning services as well as additional services through its connected partner network.

BOOK A TIGER

Exterro raised an undisclosed amount on 2022-07-25 in Private Equity Round

Exterro, Inc. is the recognized leader for legal governance, risk management, and compliance software solutions. Its solutions enable legal teams to control risks, reduce costs, enforce compliance and streamline processes by tightening collaboration between outside counsel, in-house legal teams, cross-platform business units, service providers, and resources.

Exterro pioneered e-discovery workflow management technology, and continues to expand its innovative Fusion suite of applications Genome, Legal Hold, Discovery Workflow Management, and FusionGo. The complete Fusion platform provides an end-to-end risk assessment and information management solution. Regardless of industry or system environment, Fusion integrates seamlessly with existing business processes and enterprise systems. Exterro solutions assure regulatory compliance and create sustainable ROI.

Headquartered in Portland, Oregon, Exterro has operations across the United States and abroad.

Exterro

Hoxton Farms raised $53796 on 2020-12-21 in Seed Round

Based in London, UK, Hoxton Farms is growing real animal fat – without animals. The company combines cell biology and mathematical modelling to produce cultivated fat as an ingredient for the meat alternatives industry.

Hoxton Farms

UniQure raised $58000000 on 2013-07-09 in Private Equity Round

uniQure N.V., a gene therapy company, engages in the development and commercialization of treatments for patients suffering from genetic and other diseases in the Netherlands. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington’s disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-180, an one-time intravenously-administered gene therapy candidate, which is in preclinical stage for the treatment of hemophilia A; and AMT-190, an IV-administered adeno-associated virus 5-based gene therapy for the treatment of Fabry disease. In addition, it engages in developing AMT-150, a gene therapy candidate for the treatment of Spinocerebellar Ataxia Type 3 disease. The company has collaboration and license agreements with Bristol Myers-Squibb Company; Gen-X; and Synpromics Limited. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

uniQure N.V.

Coller Capital acquires Societe Innovatech du Grand Montreal on 2004-12-10 for an undisclosed amount